Skip to main content
Delfa

← All assets

SAM-531

9 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

9

Ongoing

0

Recruiting

0

Completed

8

Sites

100

Countries

14

Endpoints

54

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 54 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1
7
Phase 2
2

Trials by status

Completed
8
Terminated
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Safety / tolerability / PK
13
Other (unclassified)
13
Memory
12
Other clinical outcomes
6
Global cognition
4
Behavior / neuropsychiatric
4
Function / daily living
2

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 6 of 54 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

ADAS-CogCognition

4

Neuropsychiatric Inventory (NPI)Behavior

2

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

9 of 9

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT00895895Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease

Donepezil, SAM-531

Alzheimer’s disease

Alzheimer's diseasePh 2Terminated96May 2011-results
NCT00481520Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease

SAM-531

Alzheimer’s disease

Alzheimer's diseasePh 2Completed7Jan 2008-
NCT00906191Study Evaluating How Quickly And To What Extent The 14-Carbon-SAM-531 Is Absorbed/Converted/Eliminated In Male Subjects

SAM-531

Alzheimer’s disease

Age 18-50Ph 1Completed1Aug 2009-
NCT00726115Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531

SAM-531

Alzheimer’s disease

Age 18-65Ph 1Completed1Feb 2009-
NCT00480818Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Young and Elderly Subjects

SAM-531

Alzheimer’s disease

Age ≥18Ph 1Completed1Jul 2007-
NCT00745576Study Evaluating The Potential Interaction Between Verapamil Immediate Release And SAM-531 When Co-Administered

SAM-531

Alzheimer’s disease

Age 18-55Ph 1Completed1Dec 2008-
NCT00479349Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531

SAM-531

Alzheimer’s disease

Age ≥20Ph 1Completed1Jan 2008-
NCT00479700Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Subjects

SAM-531

Alzheimer’s disease

Age 18-45Ph 1Completed0Jul 2006-
NCT00479297Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Japanese Males

SAM-531

Alzheimer’s disease

Age 20-45Ph 1Completed0Feb 2007-

Showing 1-9 of 9 trials